Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00656214
Other study ID # olplycopene
Secondary ID
Status Completed
Phase Phase 2
First received April 4, 2008
Last updated April 9, 2008
Start date December 2004
Est. completion date July 2006

Study information

Verified date November 2004
Source College of Dental Sciences, India
Contact n/a
Is FDA regulated No
Health authority India: Institutional Review Board
Study type Interventional

Clinical Trial Summary

the purpose of this study was to evaluate that if lycopene, a potent antioxidant can be used in the treatment of oral lichen planus. this could be useful as lycopene has no reported side effects and hence it can used in place of steroids which are commonly used for this condition and have many reported adverse effects.

lycopene can be used in the treatment of this condition as free radicals have been found to play a role in the cause of this disease and also lower levels of lycopene were seen in these patints.


Description:

Lichen planus, a chronic inflammatory mucocutaneous disease, occurs in about 2% of the adult population, affecting the skin and or oral mucosa. Clinically, lichen planus appears in keratotic, atrophic or erosive form. The atrophic and erosive forms are usually symptomatic.

Various treatment modalities viz. corticosteroids, antimicrobials, immunomodulators, phenytoin, retinoids, UV-radiation and surgical treatment etc. have been tried. Though none of these have shown to achieve satisfactory results with recurrence of lesion occurring in most of the cases after few weeks of discontinuation of therapy.

Recently a population based case control study has revealed lower levels of lycopene in atrophic and erosive oral lichen planus cases, while no significant difference was noted in any other carotenoid levels.

Lycopene is an antioxidant and free radical scavenger being used in the management of infertility, pre-eclampsia, cataract prevention, osteoarthritis, as adjuvant therapy in various malignancies, cardiovascular disorders, diabetes mellitus, aging, Alzheimer's disease, parkinsonism, etc.

Systemic lycopene has been found to be effective in treatment of oral leukoplakia, owing to its antioxidant properties.

The utility of lycopene in oral lichen planus has not been reported in the literature; therefore, this study has been designed to assess the efficacy of systemic lycopene in management of oral lichen planus patients.

The data collected from this study can move us closer to deriving a specific treatment plan for oral lichen planus - a dividend, not only for patients but dental fraternity as well.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date July 2006
Est. primary completion date May 2006
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

1. Patients who were physically healthy and well oriented in time space and as a person.

2. Patients clinically & histopathologically diagnosed to be suffering from oral lichen planus.

3. Patients who had symptoms i.e. pain and/or burning sensation secondary to oral lichen planus.

4. Patients not on any treatment for the same. In case they were, then such treatment was stopped and a washout period of two weeks was given.

5. Patients who agreed to take medication supplied.

6. Patients who were willing for evaluation once in every two weeks for 8 weeks and also agreed to follow up every 30 days for 60 days.

7. Patients who agreed for the biopsy and hematological examination.

Exclusion Criteria:

1. Patients suffering from any systemic disease/s like Diabetes, Hypertension, Cardiovascular system disease, Renal dysfunction, Liver disorders etc.

2. Patients with any other mucosal disease or any other skin disease which may be associated with oral lesions.

3. Patients on any drug therapy which may cause lichen planus like lesions.

4. Patients with findings of any physical or mental abnormality, which would interfere with or be affected by the study procedure.

5. Patients with a known allergy or contraindication to study medications.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Lycopene
08 mg/day in two divided dosage
Placebo
Two divided dosage

Locations

Country Name City State
India Department of oral medicine & radiology, College of dental sciences Davangere Karnataka

Sponsors (1)

Lead Sponsor Collaborator
College of Dental Sciences, India

Country where clinical trial is conducted

India, 

References & Publications (3)

Lycopene. Monograph. Altern Med Rev. 2003 Aug;8(3):336-42. — View Citation

Nagao T, Warnakulasuriya S, Ikeda N, Fukano H, Yamamoto S, Yano M, Miyazaki H, Ito Y. Serum antioxidant micronutrient levels in oral lichen planus. J Oral Pathol Med. 2001 May;30(5):264-7. — View Citation

Singh M, Krishanappa R, Bagewadi A, Keluskar V. Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncol. 2004 Jul;40(6):591-6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Relief from signs & symptoms of disease 08 weeks No
Secondary Relief from signs & symptoms of disease 08 weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT03320460 - Photobiomodulation in Oral Lichen Planus N/A
Completed NCT02276573 - Study of Inflammatory Role of Epstein-Barr Virus (EBV) in Atrophic and Erosive Forms of Oral Lichen Planus N/A
Recruiting NCT06158113 - Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study Phase 2
Completed NCT03687437 - Lichen Planus and Mean Platelet Volum
Completed NCT00130572 - Efficacy of Elidel Cream on Erosive Oral Lichen Planus Phase 3
Completed NCT04673916 - Treatment Protocols for Patients With Symptomatic Oral Lichen Planus N/A
Not yet recruiting NCT06362005 - The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus Phase 4
Completed NCT00102557 - Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus Phase 2
Completed NCT00133107 - Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus N/A
Completed NCT04718311 - Study on Treatment for Patients With Symptomatic Oral Lichen Planus N/A
Recruiting NCT05330572 - Clinical and Molecular Correlates of Response to First Line Treatment in Lichen Planus
Completed NCT04976673 - Comparison of Clinical Efficiency of Photodynamic Therapy and Topical Corticosteroid in Treatment of Oral Lichen Planus Phase 2
Completed NCT00746772 - Efficacy of Purslane in Treatment of Oral Lichen Planus Phase 2